On March 14, 2019, the Securities and Exchange Commission declared the Registration Statement on Form 10 of Cyclerion Therapeutics, Inc. (the “Company”), initially filed on January 28, 2019, effective. Upon the effectiveness of the Registration Statement, the Company’s board of directors (the “Board”) increased the size of the Board from two to three directors and appointed Marsha Fanucci to fill the resulting vacancy. Additionally, upon the effectiveness of the Registration Statement, Ms. Fanucci was appointed to serve on the Audit Committee of the Board. Ms. Fanucci is currently a member of the board of directors of Ironwood Pharmaceuticals, Inc. Following Ms. Fanucci’s appointment to the Board, the Board consisted of Ms. Fanucci, William Huyett and Gina Consylman.